A Study of LY3561774 in Participants With Mixed Dyslipidemia

NCT05256654 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

205

Enrollment

INDUSTRY

Sponsor class

Conditions

Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Hyperlipoproteinemia

Interventions

DRUG: LY3561774
DRUG: Placebo

Sponsor

Eli Lilly and Company